Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

Annals of Neurology

Volumn 77, Issue 3, 2015, Pages 425-435

  Kalincik, Tomas ^a,b   Horakova, Dana ^c   Spelman, Tim ^a,b   Jokubaitis, Vilija ^a   Trojano, Maria ^d   Lugaresi, Alessandra ^e   Izquierdo, Guillermo ^f   Rozsa, Csilla ^g   Grammond, Pierre ^h   Alroughani, Raed ⁱ   Duquette, Pierre ^j   Girard, Marc ^j   Pucci, Eugenio ^k   Lechner Scott, Jeannette ^l   Slee, Mark ^m   Fernandez Bolanos, Ricardo ⁿ   Grand'Maison, Francois ^o   Hupperts, Raymond ^p   Verheul, Freek ^q   Hodgkinson, Suzanne ^r   Oreja Guevara, Celia ^s   Spitaleri, Daniele ^t   Barnett, Michael ^u   Terzi, Murat ^v   Bergamaschi, Roberto ^w   McCombe, Pamela ^x   Sanchez Menoyo, Jose ^y   Simo, Magdolna ^z   Csepany, Tunde ^aa   Rum, Gabor ^ab   Boz, Cavit ^ac   Havrdova, Eva ^c   Butzkueven, Helmut ^a,b,ad   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^h Lévis Hotel Dieu   (Canada)

ⁱ AL AMIRI HOSPITAL   (Kuwait)

^j NOTRE DAME HOSPITAL   (Canada)

^k MACERATA HOSPITAL   (Italy)

^l UNIVERSITY OF NEWCASTLE   (Australia)

^m FLINDERS UNIVERSITY   (Australia)

ⁿ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^o HÔPITAL CHARLES LEMOYNE   (Canada)

^p Zuyderland Medical Centre   (Netherlands)

^q Department of Surgery   (Netherlands)

^r LIVERPOOL HOSPITAL   (Australia)

^s HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^t Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati   (Italy)

^u UNIVERSITY OF SYDNEY   (Australia)

^v ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^w C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^x ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^y HOSPITAL DE GALDAKAO   (Spain)

^z SEMMELWEIS UNIVERSITY   (Hungary)

^aa UNIVERSITY OF DEBRECEN   (Hungary)

^ab Endocrinology and Diabetology   (Hungary)

^ac KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^ad MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; QUASI EXPERIMENTAL STUDY; SENSITIVITY ANALYSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECURRENCE; REGISTRIES; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84923772724     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24339     Document Type: Article

References (34)

1. Goodin DS, Jones J, Li D, et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2012; 6:e22444.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
6. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.
7. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013; 6:CD008933.
8. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology 2010; 74(SUPPL. 3):S3-S7.
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
10. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
11. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013; 260: 2023-2032.
12. Freedman MS Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-beta therapy. Eur J Neurol 2014; 21: 377-387, e18-e20.
13. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308: 247-256.
14. Kalincik T, Spelman T, Trojano M, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013; 8:e63480.
15. Kalincik T, Jokubaitis V, Izquierdo G, et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Mult Scler 2014 Dec 5. pii: 1352458514559865 [Epub ahead of print].
16. He A, Spelman T, Jokubaitis VG, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2014 Nov 10. [Epub ahead of print].
17. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006; 12: 769-774.
18. Kalincik T, Vivek V, Jokubaitis V, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013; 136(pt 12): 3609-3617.
19. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965; 122: 552-568.
20. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999; 67: 451-456.
21. Liu C, Po ALW, Blumhardt LD. "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 726-729.
22. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
23. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal 2006; 15: 199-236.
24. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation under missing at random: a weighting approach. Stat Methods Med Res 2007; 16: 259-275.
25. Heraud-Bousquet V, Larsen C, Carpenter J, et al. Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data. BMC Med Res Methodol 2012; 12: 73.
26. Rosenbaum PR Observational studies. 2nd ed. New York, NY: Springer-Verlag, 2002.
27. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
28. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-529.
29. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
30. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-260.
31. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011; 17: 970-979.
32. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-37.
33. Belachew S, Phan Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 240-245.
34. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014; 82: 1204-1211.